{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-015944","form_type":"8-K","ticker":"VTAK","cik":"0001716621","company_name":"Catheter Precision, Inc.","filed_at":"2023-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.160189+00:00","generated_at":"2026-06-07T08:04:38.662027+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Catheter Precision reports nine-month revenue of $314K; cash at $5.6M","bullets":["Nine-month revenue $314K; total assets $32.9M; cash $5.6M as of Sep 30, 2023.","Received first approval in France; VIVO now active in six European countries.","Completed enrollment of Phase I LockeT study (>100 patients); IRB approval for Phase II randomized study.","Initiated design changes to LockeT based on feedback; new build processes for VIVO to reduce costs.","Acting CEO David Jenkins expects hospital approvals and purchase orders in coming months."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-015944","json":"https://secwatch.observer/filing/0001654954-23-015944.json","markdown":"https://secwatch.observer/filing/0001654954-23-015944.md","text":"https://secwatch.observer/filing/0001654954-23-015944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423015944/0001654954-23-015944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423015944/rmed_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T08:04:38.662027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88fc37a732cccba1377f2becb7bed14296f31501","claim":"Catheter Precision, Inc. reported three and nine months ended September 30, 2023 results: revenue $314 thousand.","evidence_excerpt":"assets at September 30, 2023, were $32.9 million. · Total cash on hand at September 30, 2023 was $5.6 million. · Total revenues for the nine months ended September 30, 2023 were $314 thousand. David Jenkins, acting CEO, commented: “We are pleased to have the Q3 financial filings completed and have a lot of momentum as we move into the fourth quarter. Our sales and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716621/000165495423015944/0001654954-23-015944-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Revenue","value":"$314 thousand"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}